The Technical Analyst
Liminal BioSciences Inc [LMNL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Liminal BioSciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.12% $8.50
America/New_York / 25 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 27.62 mill |
| EPS: | -6.83 |
| P/E: | -1.245 |
| Earnings Date: | Nov 07, 2023 |
| SharesOutstanding: | 3.25 mill |
| Avg Daily Volume: | 0.0237 mill |
| RATING 2023-09-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.245 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.245 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.46 - 8.54 ( +/- 0.48%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.50 (0.12% ) |
| Volume | 0.0051 mill |
| Avg. Vol. | 0.0237 mill |
| % of Avg. Vol | 21.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LMNL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LMNL
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Last 10 Buy Signals
Latest Press Releases
2023-09-26 08:00:00 - Press Release
Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Laval, qc and cambridge, england , sept. 26, 2023 /prnewswire/ - liminal biosciences inc. ("liminal biosciences" or the "company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the canada business corporations act involving the corporation and structured alpha lp ("salp"), a limited partnership managed by its general partner, thomvest asset management ltd.
2023-09-19 16:22:00 - Press Release
Liminal Biosciences Receives Final Court Order For Plan Of Arrangement With Structured Alpha Lp
Laval, qc and cambridge, england , sept. 19, 2023 /prnewswire/ - liminal biosciences inc. (nasdaq: lmnl) ("liminal biosciences" or the "company"), is pleased to announce that it received the final order of the ontario superior court of justice (commercial list) approving the previously-announced plan of arrangement under section 192 of the canada business corporations act (the "arrangement") pursuant to which structured alpha lp ("salp"), a limited partnership managed by its general partner, thomvest asset management ltd.
2023-09-15 11:29:00 - Press Release
Liminal Biosciences Shareholders Approve Plan Of Arrangement With Structured Alpha Lp
Laval, qc and cambridge, england , sept. 15, 2023 /prnewswire/ - liminal biosciences inc. (nasdaq: lmnl) ("liminal biosciences" or the "company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the canada business corporations act (the "arrangement") pursuant to which structured alpha lp ("salp"), a limited partnership managed by its general partner, thomvest asset management ltd.
2023-09-12 07:45:00 - Press Release
Liminal Biosciences Files Amended Schedule 13e-3 And Supplement To The Management Information Circular
Laval, qc and cambridge, england , sept. 12, 2023 /prnewswire/ - liminal biosciences inc. (nasdaq: lmnl) ("liminal biosciences" or the "company"), announced that an amendment to the previously filed schedule 13e-3 will be filed to address comments raised by the securities and exchange commission ("sec") in connection with the previously announced plan of arrangement involving the acquisition by structured alpha lp ("salp"), a limited partnership managed by its general partner, thomvest asset management ltd.
2023-08-16 16:46:00 - Press Release
Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
Laval, qc and cambridge, england , aug. 16, 2023 /prnewswire/ - liminal biosciences inc. (nasdaq: lmnl) ("liminal biosciences" or the "company"), announced today that the ontario superior court of justice (commercial list) (the "court") has issued an interim order (the "interim order") in connection with the previously-announced plan of arrangement under section 192 of the canada business corporations act (the "plan of arrangement") pursuant to which structured alpha lp ("salp"), a limited partnership managed by its general partner, thomvest asset management ltd., will acquire all of the issued and outstanding common shares of liminal biosciences (the "shares") not currently owned by salp or its affiliates and associates (the "minority shares") at a price of us$8...
Latest News
2023-07-13 12:36:14 - Zacks Investment Research
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
2023-07-12 07:48:00 - Market Watch
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
2023-04-05 10:56:47 - InvestorPlace
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
2023-04-05 08:08:00 - Market Watch
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
2023-03-17 16:08:04 - Seeking Alpha
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
2023-01-19 16:38:00 - PRNewsWire
Liminal BioSciences to Present at BIO CEO & Investor Conference
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
2022-11-13 22:17:02 - Seeking Alpha
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
2022-05-13 15:22:12 - Seeking Alpha
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
2022-05-09 08:30:00 - PRNewsWire
Liminal Biosciences to Present at Upcoming Investor Conferences
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).
2022-01-20 06:52:44 - Benzinga
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.